Cynthia Mai
Psychiatric/Mental Health · Saginaw, MINPI 1720606098
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (39.2%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Alkermes, Inc. accounts for 69.6% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $11,962, more than ten times the $215 reported in 2021. Among psychiatric/mental health clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 349 payments — averaging $45.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$11K
- Johnson & Johnson$990
- Teva Pharmaceuticals USA, Inc.$866
- Neurocrine Biosciences, Inc.$650
- Axsome Therapeutics, Inc.$567
- Lundbeck LLC$560
- plus $1K from 7 others
What the payments were for
- Consulting fees$3,71023%
- Speaking & faculty fees$4,95031%
- Travel & lodging$7145%
- Food & beverage$6,20639%
- Education$2682%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 77 | $11,031 |
| Johnson & Johnson | 44 | $990 |
| Teva Pharmaceuticals USA, Inc. | 32 | $866 |
| Neurocrine Biosciences, Inc. | 49 | $650 |
| Axsome Therapeutics, Inc. | 29 | $567 |
| Lundbeck LLC | 47 | $560 |
| AbbVie | 14 | $275 |
| Otsuka America Pharmaceutical, Inc. | 15 | $254 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $212 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $189 |
| Supernus Pharmaceuticals, Inc. | 10 | $170 |
| E.r. Squibb & Sons, L.L.C. | 3 | $54 |
| Sunovion Pharmaceuticals Inc. | 3 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$37,362
- UZEDY$225
- INVEGA SUSTENNA$140
How this compares
$15,848 in reported general payments places this provider in the 95th percentile of 638 psychiatric/mental health providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $127,101 |
| Invega TrinzaPaliperidone Palmitate | 14 | $85,759 |
| Invega SustennaPaliperidone Palmitate | 33 | $79,471 |
| RexultiBrexpiprazole | 52 | $72,547 |
| UzedyRisperidone | 18 | $46,439 |
| AristadaAripiprazole Lauroxil | 13 | $42,297 |
| Abilify MaintenaAripiprazole | 13 | $38,602 |
| TrintellixVortioxetine Hydrobromide | 28 | $17,598 |
| VraylarCariprazine Hcl | 11 | $16,793 |
| Risperdal ConstaRisperidone Microspheres | 25 | $15,715 |
| Paliperidone ErPaliperidone | 63 | $8,045 |
| Lurasidone Hcl | 64 | $7,829 |
| Divalproex Sodium ErDivalproex Sodium | 109 | $5,153 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,701 |
| Fluphenazine Hcl | 43 | $3,790 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Risperdal Consta | $990 | $180,94472 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $650 | $127,10114 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $254 | $111,14965 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $866 | $46,43918 claims |
| Alkermes, Inc.Aristada | $11,031 | $42,29713 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $189 | $22,30040 claims |
| AbbVieVraylar | $275 | $16,79311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 638 psychiatric/mental health providers in Michigan.
Other psychiatric/mental health in Saginaw
- Gladys KimeliSaginaw$17K
- Abraham KimeliSaginaw$13K
- Melissa WaznySaginaw$7K
- Amber FritzlerSaginaw$5K
- Duren GutierrezSouthfield$207K
- Tamlynn EvansTraverse City$78K
- Shiba NixonClarkston$60K
- Amy AmesClinton Township$43K
- Cody ShinavierClarkston$41K
- Oksana LidkeBattle Creek$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.